Akèy › Limfòm selil B › Minnesota
Etid klinik pou Limfòm selil B nan Minnesota
12 etid pou Limfòm selil B ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06634589A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Research Site, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07123454A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT03017820CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 9, 2026 · NCT04892277BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- University of Minnesota, Minneapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT05370430Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Oct 14, 2025 · NCT00626496Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital and Clinics of Minnesota, Minneapolis
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.